Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial

Abstract

Background:Breast cancer becomes lethal when visceral metastases develop. At this stage, anti-cancer treatments aim at relieving symptoms and delaying death without resulting in additional toxicity. On the basis of their differential anti-oxidant defence level, tumour cells can be made more sensitive to chemotherapy than non-tumour cells when membrane lipids are enriched with docosahexaenoic acid (DHA), a peroxidisable and oxidative-stress-inducing lipid of marine origin.Methods:This open-label single-arm phase II study evaluated the safety and efficacy (response rate), as primary end points, of the addition of 1.8 g DHA daily to an anthracycline-based chemotherapy (FEC) regimen in breast cancer patients (n=25) with rapidly progressing visceral metastases. The secondary end points were time to progression (TTP) and overall survival (OS).Results:The objective response rate was 44%. With a mean follow-up time of 31 months (range 2–96 months), the median TTP was 6 months. Median OS was 22 months and reached 34 months in the sub-population of patients (n=12) with the highest plasma DHA incorporation. The most common grade 3 or 4 toxicity was neutropaenia (80%).Conclusion:DHA during chemotherapy was devoid of adverse side effects and can improve the outcome of chemotherapy when highly incorporated. DHA has a potential to specifically chemosensitise tumours.

DOI: 10.1038/sj.bjc.6605441

Extracted Key Phrases

4 Figures and Tables

010020030020102011201220132014201520162017
Citations per Year

1,024 Citations

Semantic Scholar estimates that this publication has 1,024 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Bougnoux2009ImprovingOO, title={Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial}, author={Philippe Bougnoux and Naoufel Hajjaji and M N Ferrasson and B. Giraudeau and Charles Couet and Olivier le Floch}, journal={British Journal of Cancer}, year={2009}, volume={101}, pages={1978 - 1985} }